Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: Guidelines of the LUTS committee of the French urological association;Bilan initial, suivi et traitement des troubles mictionnels en rapport avec hyperplasie bénigne de prostate : Recommandations du CTMH de l'AFU

Progres en Urologie

Volumn 22, Issue 16, 2012, Pages 977-988

  Descazeaud, A ^a,b   Robert, G ^c   Delongchamps, N B ^d   Cornu, J N ^e   Saussine, C ^f   Haillot, O ^g   Devonec, M ^h   Fourmarier, M ⁱ   Ballereau, C ^j   Lukacs, B ^e   Dumonceau, O ^k   Azzouzi, A R ^l   Faix, A ^m   Desgrandchamps, F ⁿ   de la Taille, A ^o,p  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d Assistance publique Hôpitaux de Paris ^*  (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ Centre hospitalier Aix en Provence   (France)

^j Ramsay Santé   (France)

^k SAINT JOSEPH HOSPITAL   (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

^m Clinique mutualiste Beausoleil   (France)

ⁿ SAINT LOUIS HOSPITAL   (France)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^p INSERM   (France)

more..

Author keywords

Benign prostatic hyperplasia; Guidelines; Lower urinary tract symptoms

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

BLOOD; DRUG COMBINATION; FRANCE; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; METHODOLOGY; PRACTICE GUIDELINE; PROSTATE HYPERTROPHY; PROSTATECTOMY; RISK ASSESSMENT; SHORT SURVEY; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; BIOLOGICAL MARKERS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG THERAPY, COMBINATION; FRANCE; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84870244883     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2012.10.001     Document Type: Short Survey

References (58)

1. Descazeaud A., Robert G., Barry Delongchamps N., et al. Bilan initial et suivi de l'hyperplasie bénigne de prostate : revue de littérature du CTMH de l'AFU. Prog Urol 2012, 22:1-6.
2. Robert G., Descazeaud A., Barry Delongchamps N., et al. Traitement médical de l'hyperplasie bénigne de la prostate : revue de littérature par le CTMH/AFU. Prog Urol 2012, 22:7-12.
3. Barry Delongchamps N., Robert G., Descazeaud A., et al. Traitement de l'hyperplasie bénigne de prostate par techniques endoscopiques électriques et adénomectomie voie haute : revue de littérature du CTMH de l'AFU. Prog Urol 2012, 22:73-79.
4. Barry Delongchamps N., Robert G., Descazeaud A., et al. Traitement chirurgical de l'hyperplasie bénigne de la prostate par laser : revue de littérature du CTMH de l'AFU. Prog Urol 2012, 22:80-86.
5. Barry Delongchamps N., Robert G., Descazeaud A., et al. Traitement chirurgical de l'hyperplasie bénigne de la prostate par thermothérapie et autres techniques émergentes : revue de littérature du CTMH de l'AFU. Prog Urol 2012, 22:87-92.
6. McVary K.T., Roehrborn C.G., Avins A.L., Barry M.J., Bruskewitz R.C., Donnell R.F., et al. Update on AUA Guideline on the management of benign prostatic hyperplasia. J Urol 2011, 185:1793-1803.
7. Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the treatment of non-neurogenic Male LUTS. European Association of Urology. http://www.uroweb.org/gls/pdf/12_Male_LUTS.pdf.
8. Jones C., Hill J., Chapple C. Management of lower urinary tract symptoms in men: summary of NICE guidance. BMJ 2010, 340:c2354.
9. Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia. Chatelain C, Denis L, Foo JKT, Khoury KS, McConnell J, et al. United Kingdom: Plymbridge Distributors, Ltd., 2001.
10. Recommandations diagnostique et thérapeutique de l'hypertrophie bénigne de prostate. Agence nationale d'accréditation et d'évaluation en santé. Mars 2003. http://www.has-sante.fr/.
11. OCEBM Levels of Evidence Working Group*. " The Oxford 2011 Levels of Evidence" Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx%3Fo=5653.
12. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167-178.
13. Haab F., Amarenco G., Coloby P., Grise P., Jacquetin B., Labat J.J., et al. Terminologie des troubles fonctionnels du bas appareil urinaire : adaptation française de la terminologie de l'International Continence Society. Prog Urol 2004, 14:1103-1111.
14. Fitzpatrick J.M. The natural history of benign prostatic hyperplasia. BJU Int 2006, 97(Suppl. 2):3-6. [discussion 21-22].
15. Flanigan R.C., Reda D.J., Wasson J.H., Anderson R.J., Abdellatif M., Bruskewitz R.C. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a department of veterans affairs cooperative study. J Urol 1998, 160(1):12-16. [discussion 16-17].
16. Brown C.T., Yap T., Cromwell D.A., Rixon L., Steed L., Mulligan K., et al. Self-management for men with lower urinary tract symptoms: randomised controlled trial. BMJ 2007, 334(7583):25.
17. Brown C.T., van der Meulen J., Mundy A.R., O'Flynn E., Emberton M. Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. Eur Urol 2004, 46(2):254-262. [discussion 263].
18. Wilt T.J., Howe R.W., Rutks I.R., MacDonald R. Terazosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002, 4:CD003851.
19. Wilt T.J., Mac Donald R., Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003, 1:CD002081.
20. Chapple C.R., Montorsi F., Tammela T.L., Wirth M., Koldewijn E., Fernandez Fernandez E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011, 59(3):342-352.
21. Vallancien G., Emberton M., Alcaraz A., Matzkin H., van Moorselaar R.J., Hartung R., et al. Alfuzosin 10mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 2008, 101(7):847-852.
22. Narayan P., Tewari A. Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology 1998, 51(4A Suppl.):38-45.
23. McNeill S.A., Hargreave T.B., Roehrborn C.G. Alfuzosin 10mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 2005, 65(1):83-89. [discussion 89-90].
24. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349(25):2387-2398.
25. McConnell J.D., Bruskewitz R., Walsh P., Andriole G., Lieber M., Holtgrewe H.L., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338(9):557-563.
26. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996, 48(3):398-405.
27. Roehrborn C.G., Siami P., Barkin J., Damiao R., Major-Walker K., Nandy I., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010, 57(1):123-131.
28. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349(3):215-224.
29. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004, 172(4 Pt. 1):1314-1317.
30. Tacklind J., MacDonald R., Rutks I., Wilt T.J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009, 2:CD001423.
31. Wilt T., Ishani A., Mac Donald R., Rutks I., Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002, 1:CD001044.
32. MacDonald R., Tacklind J.W., Tutks I., et al. Serenoa repens monotherapy for benign prostatic hyperplasie (BPH): an updated Cochrane systematic review. BJU Int 2012, 109:1756-1761.
33. MacDiarmid S.A., Peters K.M., Chen A., Armstrong R.B., Orman C., Aquilina J.W., et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008, 83(9):1002-1010.
34. Kaplan S.A., Roehrborn C.G., Rovner E.S., Carlsson M., Bavendam T., Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296(19):2319-2328.
35. Chapple C., Herschorn S., Abrams P., Sun F., Brodsky M., Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009, 56(3):534-541.
36. Martínez-Salamanca J.I., Carballido J., Eardley I., Giuliano F., Gratzke C., Rosen R., et al. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol 2011, 60(3):527-535.
37. Lourenco T., Armstrong N., N'Dow J., et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess 2008, 12:1-146.
38. Madersbacher S., Lackner J., Brossner C., et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol 2005, 47:499-504.
39. Ho H.S., Yip S.K., Lim K.B., Fook S., Foo K.T., Cheng C.W. A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system. Eur Urol 2007, 52(2):517-522.
40. Mamoulakis C., Skolarikos A., Schulze M., et al. Results from an international multicentre double-blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate. BJU Int 2012, 109(2):240-248.
41. Yang Q., Peters T.J., Donovan J.L., et al. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomised controlled trials. J Urol 2001, 165:1526-1532.
42. Skolarikos A., Papachristou C., Athanasiadis G., et al. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol 2008, 22:2333-2340.
43. Capitán C., Blázquez C., Martin M.D., Hernández V., de la Peña E., Llorente C. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up. Eur Urol 2011, 60(4):734-739.
44. Descazeaud A., Robert G., Azzousi A.R., et al. Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review. BJU Int 2009, 103(9):1162-1165.
45. Lukacs B., Loeffler J., Bruyère F., et al. Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol 2012, 61(6):1165-1173.
46. Naspro R., Bachmann A., Gilling P., Kuntz R., Madersbacher S., Montorsi F., et al. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol 2009, 55(6):1345-1357.
47. Hoffman R.M., MacDonald R., Wilt T.J. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev 2004, 1.
48. Westenberg A., Gilling P., Kennett K., Frampton C., Fraundorfer M. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term follow-up. J Urol 2004, 172:616-619.
49. Kuntz R.M., Lehrich K., Ahyai S.A. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008, 53:160-166.
50. Elmansy H., Baazeem A., Kotb A., Badawy H., Riad E., Emran A., et al. Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60ml: preliminary results of a prospective, randomized clinical trial. J Urol 2012, 188(1):216-221.
51. Xia S.J., Zhuo J., Sun X.W., Han B.M., Shao Y., Zhang Y.N. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol 2008, 53:382-390.
52. Hammadeh M.Y., Madaan S., Hines J., Philp T. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology 2003, 61:1166-1171.
53. Hoffman R.M., Monga M., Elliot S., et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev 2007, 17(4):CD004135.
54. Zlotta A.R., Giannakopoulos X., Maehlum O., Ostrem T., Schuman C.C., et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003, 44:89-93.
55. Armitage J.N., Cathcart P.J., Rashidian A., et al. Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J Urol 2007, 177:1619-1624.
56. Maria G., Brisinda G., Civello I.M., et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62:259-264.
57. Plante M.K., Marks L.S., Anderson R., Amling C., Rukstalis D., Badlani G., et al. Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 2007, 177(3):1030-1035.
58. Grise P., Plante M., Palmer J., Martinez-Sagarra J., Hernandez C., Schettini M., et al. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 2004, 46(4):496-501.